Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1057557 | 0.95 | PTGER2 (1.00) | PTGER2PTGER4 | |
| SCHEMBL4085414 | 0.86 | PTGER4 (0.92) | PTGER2PTGER4 | |
| SCHEMBL4087582 | 0.86 | PTGER2 (0.74) | PTGER2PTGER4 | |
| SCHEMBL1057158 | 0.84 | PTGER2 (1.00) | PTGER2PTGER4 | |
| SCHEMBL1050702 | 0.84 | PTGER2 (1.00) | PTGER2PTGER4 | |
| SCHEMBL1055986 | 0.84 | PTGER2 (1.00) | PTGER2PTGER4 | |
| SCHEMBL1055159 | 0.84 | PTGER2 (0.80) | PTGER2PTGER4 | |
| SCHEMBL1056041 | 0.84 | PTGER2 (1.00) | PTGER2PTGER4 | |
| SCHEMBL28798194 | 0.84 | PTGER4 (0.65) | PTGER2PTGER4 | |
| SCHEMBL27856603 | 0.83 | PTGER4 (0.64) | PTGER2PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1847533-B1 | SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2013-08-14 | — | — | EP | disclosed |
| CN-101133037-B | Six-membered heterocyclic compound and use thereof | ASAHI KASEI PHARMA CORP | 2012-05-09 | — | — | CN | disclosed |
| WO-2009117831-A9 | HYBRID MOLECULES HAVING MIXED VITAMIN D RECEPTOR AGONISM AND HISTONE DEACETYLASE INHIBITORY PROPERTIES | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2009-12-30 | — | — | WO | disclosed |
| US-7531533-B2 | 6-Membered heterocyclic compound and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-05-12 | — | — | US | disclosed |
| EP-1847533-A1 | SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2007-10-24 | — | — | EP | disclosed |
| US-20070060590-A1 | 6-Membered heterocyclic compound and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060590-A1 | 6-Membered heterocyclic compound and use thereof | WNT1, CYP11B2, CYP11B1 | PTGER2 39/4885PTGER4 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.